Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-27	JP¥32.00	0.00%	245,200
26-07-27	JP¥32.00	0.00%	741,200
26-07-24	JP¥32.00	-5.88%	1,657,300
26-07-23	JP¥34.00	+3.03%	4,954,400
26-07-22	JP¥33.00	0.00%	259,200

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Delayed Japan Exchange Other stock markets 20:34:55 2026-07-27 EDT			5-day change	1st Jan Change
32.00 ^JPY	0.00%		-3.03%	-42.86%

06-11	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-26	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC	CI

Market Cap	3.11B 19.03M 16.73M 15.57M 14.3M 26.86M 1.82B 27.21M 185M 72.3M 901M 71.44M 69.9M	P/E 2024	-3.57x	P/E 2025	-2.01x
Enterprise Value	303M 1.85M 1.63M 1.51M 1.39M 2.61M 177M 2.64M 17.99M 7.03M 87.58M 6.94M 6.79M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	91.07%	Yield 2024 *	-	Yield 2025	-

06-11	Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-26	Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC	CI
05-13	Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
02-12	Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-25	Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC	CI
25-08-06	Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC	CI
25-07-06	Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment	MT
25-06-15	Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan	MT
25-06-09	SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy	CI
25-04-30	Modalis Issues 21,900 Shares for Restricted Stock Remuneration	MT
25-01-27	Modalis Therapeutics Secures Japanese Patent for Gene Therapy	MT
25-01-06	JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Research for CNS Disease	MT
25-01-05	Jcr Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation Announces Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	CI

12-24	Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD	BU
25-05-12	Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.	BU
25-01-05	JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy	BU
24-10-28	Modalis Therapeutics - MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a has been granted Orphan Drug Designation in the US by the Food and Drug Administration	AQ
24-10-25	Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).	BU

Modalis Therapeutics Corporation Stock

Stocks

4883

JP3922600006

Biotechnology & Medical Research

Valuation: Modalis Therapeutics Corporation

Chart: Modalis Therapeutics Corporation

Latest news : Modalis Therapeutics Corporation

Press Releases: Modalis Therapeutics Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Modalis Therapeutics Corporation

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	-3.03%
Current month	-3.03%
3 months	-51.52%
6 months	-46.67%
Current year	-42.86%

1 week	31	38
1 month	30	39
Current year	30	83
1 year	30	97
3 years	30	234
5 years	30	1,667
10 years	30	4,070

Manager	Title	Age	Since
Haru Morita CEO	Chief Executive Officer	56	2015-12-31
Naoki Kobayashi DFI	Director of Finance/CFO	62	-
Tetsuya Yamagata CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Haru Morita BRD	Director/Board Member	56	2015-12-31
Osamu Nureki BRD	Director/Board Member	60	2015-12-31
Hideki Takeda BRD	Director/Board Member	67	2015-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/24/24	Osamu Nureki	Others	Founder	10,000	0.0220%
9/24/24	Osamu Nureki	Others	Founder	10,000	0.0220%
9/24/24	Osamu Nureki	Others	Founder	375,600	0.8278%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MODALIS THERAPEUTICS CORPORATION	0.00%	-3.03%	-65.22%	-85.25%	19.03M
ARGENX SE	-1.82%	+4.80%	+56.71%	+68.36%	57.28B
WUXI APPTEC CO., LTD.	-0.27%	+5.74%	+40.26%	+80.17%	54.99B
INSMED INCORPORATED	-2.05%	-2.14%	+0.75%	+413.38%	23.18B
BIONTECH SE	+1.97%	-1.16%	-21.00%	-13.25%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-1.13%	+1.05%	+22.73%	-7.73%	20.46B
GENMAB A/S	+1.57%	+3.30%	+28.01%	-29.07%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.10%	+1.88%	+38.63%	+545.91%	15.67B
PHARMAESSENTIA CORPORATION	+5.29%	0.00%	+185.09%	+332.66%	14.46B
EXELIXIS, INC.	+0.79%	+0.50%	+22.39%	+184.74%	13.92B
Average	+0.42%	+1.05%	+30.83%	+148.99%	24.01B
Weighted average by Cap.	-0.13%	+1.53%	+39.79%	+136.89%

	2024	2025
Net sales	-	-
Net income	-1.32B -8.05M -7.07M -6.58M -6.05M -11.36M -772M -11.51M -78.27M -30.57M -381M -30.21M -29.56M	-2.15B -13.15M -11.56M -10.76M -9.88M -18.56M -1.26B -18.8M -128M -49.95M -623M -49.36M -48.29M
Net Debt	-3.58B -21.84M -19.2M -17.87M -16.42M -30.82M -2.09B -31.23M -212M -82.98M -1.03B -82M -80.23M	-2.81B -17.18M -15.1M -14.06M -12.91M -24.25M -1.65B -24.57M -167M -65.27M -814M -64.5M -63.11M